Deguchi K, Murashima S, Shirakawa S, Soria C, Soria J, Dunn F, Tobelem G
Thromb Res. 1985 Dec 15;40(6):853-61. doi: 10.1016/0049-3848(85)90321-4.
A new role for platelets in fibrinolysis is proposed. Platelets (euglobulin from platelet rich plasma and from human platelet extract) may potentiate plasminogen activation by tissue plasminogen activator (tPA). The potentiating activity was detected by both chromogenic substrate and fibrin plate analysis. The fibrinolysis-potentiating substance in the platelets required the presence of both tPA and plasminogen, suggesting that it potentiates the activation of plasminogen by tPA. This substance was not related to fibrinogen degradation products because it was also present in platelets from two afibrinogenemic patients and did not lose its activity when separated from fibrinogen-related antigen by Sepharose 2B gel filtration. Since platelets contain both activator(s) and inhibitor(s) of plasminogen activation by tPA, a balance between activator(s) and inhibitor(s) in platelets may also be required for control of the fibrinolytic pathway.
有人提出血小板在纤维蛋白溶解过程中具有新作用。血小板（富含血小板血浆和人血小板提取物中的优球蛋白）可能增强组织型纤溶酶原激活剂（tPA）对纤溶酶原的激活作用。通过发色底物分析和纤维蛋白平板分析均检测到了这种增强活性。血小板中具有纤维蛋白溶解增强作用的物质需要同时存在tPA和纤溶酶原，这表明它增强了tPA对纤溶酶原的激活作用。该物质与纤维蛋白原降解产物无关，因为在两名无纤维蛋白原血症患者的血小板中也存在该物质，并且通过琼脂糖2B凝胶过滤与纤维蛋白原相关抗原分离时其活性并未丧失。由于血小板同时含有tPA激活纤溶酶原的激活剂和抑制剂，因此血小板中激活剂和抑制剂之间的平衡对于控制纤维蛋白溶解途径可能也是必需的。
